Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 128

1.

Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study.

Heppt MV, Amaral T, Kähler KC, Heinzerling L, Hassel JC, Meissner M, Kreuzberg N, Loquai C, Reinhardt L, Utikal J, Dabrowski E, Gesierich A, Pföhler C, Terheyden P, Thoms KM, Zimmer L, Eigentler TK, Kirchberger MC, Stege HM, Meier F, Schlaak M, Berking C.

J Immunother Cancer. 2019 Nov 13;7(1):299. doi: 10.1186/s40425-019-0800-0.

2.

C-reactive protein as an early marker of immune-related adverse events.

Abolhassani AR, Schuler G, Kirchberger MC, Heinzerling L.

J Cancer Res Clin Oncol. 2019 Oct;145(10):2625-2631. doi: 10.1007/s00432-019-03002-1. Epub 2019 Sep 6.

PMID:
31492984
3.

Non-professional phagocytosis: a general feature of normal tissue cells.

Seeberg JC, Loibl M, Moser F, Schwegler M, Büttner-Herold M, Daniel C, Engel FB, Hartmann A, Schlötzer-Schrehardt U, Goppelt-Struebe M, Schellerer V, Naschberger E, Ganzleben I, Heinzerling L, Fietkau R, Distel LV.

Sci Rep. 2019 Aug 15;9(1):11875. doi: 10.1038/s41598-019-48370-3.

4.

Myocarditis in the Setting of Cancer Therapeutics: Proposed Case Definitions for Emerging Clinical Syndromes in Cardio-Oncology

Bonaca MP, Olenchock BA, Salem JE, Wiviott SD, Ederhy S, Cohen A, Stewart GC, Choueiri TK, Di Carli M, Allenbach Y, Kumbhani DJ, Heinzerling L, Amiri-Kordestani L, Lyon AR, Thavendiranathan P, Padera R, Lichtman A, Liu PP, Johnson DB, Moslehi J.

Circulation. 2019 Jul 2;140(2):80-91.

PMID:
31390169
5.

In Reply.

Heinzerling L.

Dtsch Arztebl Int. 2019 May 17;116(20):363-364. doi: 10.3238/arztebl.2019.0363b. No abstract available.

6.

Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management.

Heinzerling L, Eigentler TK, Fluck M, Hassel JC, Heller-Schenck D, Leipe J, Pauschinger M, Vogel A, Zimmer L, Gutzmer R.

ESMO Open. 2019 May 23;4(3):e000491. doi: 10.1136/esmoopen-2019-000491. eCollection 2019. Review.

7.

Checkpoint inhibitor-induced eosinophilic fasciitis following high eosinophilia associated with complete response.

Toussaint F, Hammon M, Erdmann M, Moreira A, Kirchberger MC, Schuler G, Schett G, Heinzerling L.

Rheumatology (Oxford). 2019 Oct 1;58(10):1875-1877. doi: 10.1093/rheumatology/kez164. No abstract available.

PMID:
31056673
8.

Checkpoint Inhibitors.

Heinzerling L, de Toni EN, Schett G, Hundorfean G, Zimmer L.

Dtsch Arztebl Int. 2019 Feb 22;116(8):119-126. doi: 10.3238/arztebl.2019.0119.

9.

Adverse events 2.0-Let us get SERIOs: New reporting for adverse event outcomes needed in the era of immunooncology.

Heinzerling L, Ascierto PA, Dummer R, Gogas H, Grob JJ, Lebbe C, Long GV, McArthur G, Moslehi JJ, Neilan TG, Ribas A, Robert C, Schadendorf D, Wolchok JD, Hauschild A.

Eur J Cancer. 2019 May;112:29-31. doi: 10.1016/j.ejca.2019.01.015. Epub 2019 Mar 21. No abstract available.

PMID:
30903870
10.

Characterization of tanning behavior assessed via online survey: Attitudes, habits, and preventive measures with focus on sunscreen use.

Schneiderbanger CK, Schuler G, Heinzerling L, Kirchberger MC.

Photodermatol Photoimmunol Photomed. 2019 Jul;35(4):268-274. doi: 10.1111/phpp.12465. Epub 2019 Mar 25.

PMID:
30854722
11.

Eosinophil-cationic protein - a novel liquid prognostic biomarker in melanoma.

Krückel A, Moreira A, Fröhlich W, Schuler G, Heinzerling L.

BMC Cancer. 2019 Mar 7;19(1):207. doi: 10.1186/s12885-019-5384-z.

12.

Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors.

Awadalla M, Golden DLA, Mahmood SS, Alvi RM, Mercaldo ND, Hassan MZO, Banerji D, Rokicki A, Mulligan C, Murphy SPT, Jones-O'Connor M, Cohen JV, Heinzerling LM, Armanious M, Sullivan RJ, Damrongwatanasuk R, Chen CL, Gupta D, Kirchberger MC, Moslehi JJ, Shah SP, Ganatra S, Thavendiranathan P, Rizvi MA, Sahni G, Lyon AR, Tocchetti CG, Mercurio V, Thuny F, Ederhy S, Mahmoudi M, Lawrence DP, Groarke JD, Nohria A, Fradley MG, Reynolds KL, Neilan TG.

J Immunother Cancer. 2019 Feb 22;7(1):53. doi: 10.1186/s40425-019-0535-y.

13.

Sequence-dependent cross-resistance of combined radiotherapy plus BRAFV600E inhibition in melanoma.

Shannan B, Matschke J, Chauvistré H, Vogel F, Klein D, Meier F, Westphal D, Bruns J, Rauschenberg R, Utikal J, Forschner A, Berking C, Terheyden P, Dabrowski E, Gutzmer R, Rafei-Shamsabadi D, Meiss F, Heinzerling L, Zimmer L, Livingstone E, Váraljai R, Hoewner A, Horn S, Klode J, Stuschke M, Scheffler B, Marchetto A, Sannino G, Grünewald TGP, Schadendorf D, Jendrossek V, Roesch A.

Eur J Cancer. 2019 Mar;109:137-153. doi: 10.1016/j.ejca.2018.12.024. Epub 2019 Feb 2.

PMID:
30721788
14.

Age as key factor for pattern, timing, and extent of distant metastasis in patients with cutaneous melanoma: A study of the German Central Malignant Melanoma Registry.

Gassenmaier M, Keim U, Leiter U, Eigentler TK, Röcken M, Gesierich A, Moritz RKC, Heinzerling L, Tüting T, Wollina U, Garbe C.

J Am Acad Dermatol. 2019 May;80(5):1299-1307.e7. doi: 10.1016/j.jaad.2019.01.044. Epub 2019 Jan 29.

PMID:
30703453
15.

Detection and Characterization of Circulating Tumor Cells in Patients with Merkel Cell Carcinoma.

Riethdorf S, Hildebrandt L, Heinzerling L, Heitzer E, Fischer N, Bergmann S, Mauermann O, Waldispühl-Geigl J, Coith C, Schön G, Peine S, Schuler G, Speicher MR, Moll I, Pantel K.

Clin Chem. 2019 Mar;65(3):462-472. doi: 10.1373/clinchem.2018.297028. Epub 2019 Jan 9.

PMID:
30626636
16.

Strengthened scientific support for the Endangerment Finding for atmospheric greenhouse gases.

Duffy PB, Field CB, Diffenbaugh NS, Doney SC, Dutton Z, Goodman S, Heinzerling L, Hsiang S, Lobell DB, Mickley LJ, Myers S, Natali SM, Parmesan C, Tierney S, Williams AP.

Science. 2019 Feb 8;363(6427). pii: eaat5982. doi: 10.1126/science.aat5982. Epub 2018 Dec 13. Review.

PMID:
30545843
17.

c-Rel is a cell cycle modulator in human melanoma cells.

Priebe MK, Dewert N, Amschler K, Erpenbeck L, Heinzerling L, Schön MP, Seitz CS, Lorenz VN.

Exp Dermatol. 2019 Feb;28(2):121-128. doi: 10.1111/exd.13848. Epub 2018 Dec 21.

PMID:
30466153
18.

Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors.

Moreira A, Loquai C, Pföhler C, Kähler KC, Knauss S, Heppt MV, Gutzmer R, Dimitriou F, Meier F, Mitzel-Rink H, Schuler G, Terheyden P, Thoms KM, Türk M, Dummer R, Zimmer L, Schröder R, Heinzerling L.

Eur J Cancer. 2019 Jan;106:12-23. doi: 10.1016/j.ejca.2018.09.033. Epub 2018 Nov 17.

PMID:
30453170
19.

Centrosomal protein TRIM43 restricts herpesvirus infection by regulating nuclear lamina integrity.

Full F, van Gent M, Sparrer KMJ, Chiang C, Zurenski MA, Scherer M, Brockmeyer NH, Heinzerling L, Stürzl M, Korn K, Stamminger T, Ensser A, Gack MU.

Nat Microbiol. 2019 Jan;4(1):164-176. doi: 10.1038/s41564-018-0285-5. Epub 2018 Nov 12.

20.

Senescence markers: Predictive for response to checkpoint inhibitors.

Moreira A, Gross S, Kirchberger MC, Erdmann M, Schuler G, Heinzerling L.

Int J Cancer. 2019 Mar 1;144(5):1147-1150. doi: 10.1002/ijc.31763. Epub 2018 Dec 4.

PMID:
30151962
21.

Fear of cancer progression in patients with stage IA malignant melanoma.

Wagner T, Augustin M, Blome C, Forschner A, Garbe C, Gutzmer R, Hauschild A, Heinzerling L, Livingstone E, Loquai C, Schadendorf D, Terheyden P, Mueller-Brenne T, Kähler KC.

Eur J Cancer Care (Engl). 2018 Sep;27(5):e12901. doi: 10.1111/ecc.12901. Epub 2018 Aug 20.

PMID:
30126009
22.

[Neurological side effects of checkpoint inhibitors].

Knauss S, Ginesta Roque L, Hühnchen P, Heinzerling L, Böhmerle W, Endres M.

Nervenarzt. 2019 Feb;90(2):138-147. doi: 10.1007/s00115-018-0571-8. German.

PMID:
30073487
23.

Real world experience in low-dose ipilimumab in combination with PD-1 blockade in advanced melanoma patients.

Kirchberger MC, Moreira A, Erdmann M, Schuler G, Heinzerling L.

Oncotarget. 2018 Jun 22;9(48):28903-28909. doi: 10.18632/oncotarget.25627. eCollection 2018 Jun 22.

24.

The outweigh of toxicity versus risk of recurrence for adjuvant interferon therapy: a survey in German melanoma patients and their treating physicians.

Kähler KC, Blome C, Forschner A, Gutzmer R, Hauschild A, Heinzerling L, Livingstone E, Loquai C, Müller-Brenne T, Schadendorf D, Utikal J, Wagner T, Augustin M.

Oncotarget. 2018 May 25;9(40):26217-26225. doi: 10.18632/oncotarget.25439. eCollection 2018 May 25.

25.

MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patients.

Kirchberger MC, Ugurel S, Mangana J, Heppt MV, Eigentler TK, Berking C, Schadendorf D, Schuler G, Dummer R, Heinzerling L.

Eur J Cancer. 2018 Jul;98:10-16. doi: 10.1016/j.ejca.2018.04.010. Epub 2018 May 26.

PMID:
29843107
26.

Willingness to pay for a cure of low-risk melanoma patients in Germany.

Augustin M, Blome C, Forschner A, Gutzmer R, Hauschild A, Heinzerling L, Livingstone E, Loquai C, Schadendorf D, Utikal J, Wagner T, Wilden S, Kähler KC.

PLoS One. 2018 May 24;13(5):e0197780. doi: 10.1371/journal.pone.0197780. eCollection 2018.

27.

Effective anti-programmed death-1 therapy in a SUFU-mutated patient with Gorlin-Goltz syndrome.

Moreira A, Kirchberger MC, Toussaint F, Erdmann M, Schuler G, Heinzerling L.

Br J Dermatol. 2018 Sep;179(3):747-749. doi: 10.1111/bjd.16607. Epub 2018 Jun 26.

PMID:
29603722
28.

Myocarditis in Patients Treated With Immune Checkpoint Inhibitors.

Mahmood SS, Fradley MG, Cohen JV, Nohria A, Reynolds KL, Heinzerling LM, Sullivan RJ, Damrongwatanasuk R, Chen CL, Gupta D, Kirchberger MC, Awadalla M, Hassan MZO, Moslehi JJ, Shah SP, Ganatra S, Thavendiranathan P, Lawrence DP, Groarke JD, Neilan TG.

J Am Coll Cardiol. 2018 Apr 24;71(16):1755-1764. doi: 10.1016/j.jacc.2018.02.037. Epub 2018 Mar 19.

29.

BRAF Inhibitors and Radiation Do Not Act Synergistically to Inhibit WT and V600E BRAF Human Melanoma.

Walter L, Heinzerling L.

Anticancer Res. 2018 Mar;38(3):1335-1341.

PMID:
29491057
30.

Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders.

Kähler KC, Eigentler TK, Gesierich A, Heinzerling L, Loquai C, Meier F, Meiss F, Pföhler C, Schlaak M, Terheyden P, Thoms KM, Ziemer M, Zimmer L, Gutzmer R; German Dermatologic Cooperative Oncology Group (DeCOG).

Cancer Immunol Immunother. 2018 May;67(5):825-834. doi: 10.1007/s00262-018-2134-z. Epub 2018 Feb 27.

PMID:
29487980
31.

Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients.

Hecht M, Meier F, Zimmer L, Polat B, Loquai C, Weishaupt C, Forschner A, Gutzmer R, Utikal JS, Goldinger SM, Geier M, Hassel JC, Balermpas P, Kiecker F, Rauschenberg R, Dietrich U, Clemens P, Berking C, Grabenbauer G, Schadendorf D, Grabbe S, Schuler G, Fietkau R, Distel LV, Heinzerling L.

Br J Cancer. 2018 Mar 20;118(6):785-792. doi: 10.1038/bjc.2017.489. Epub 2018 Feb 13.

32.

A web platform for the network analysis of high-throughput data in melanoma and its use to investigate mechanisms of resistance to anti-PD1 immunotherapy.

Dreyer FS, Cantone M, Eberhardt M, Jaitly T, Walter L, Wittmann J, Gupta SK, Khan FM, Wolkenhauer O, Pützer BM, Jäck HM, Heinzerling L, Vera J.

Biochim Biophys Acta Mol Basis Dis. 2018 Jun;1864(6 Pt B):2315-2328. doi: 10.1016/j.bbadis.2018.01.020. Epub 2018 Feb 23.

33.

BRAF and MEK Inhibitors Influence the Function of Reprogrammed T Cells: Consequences for Adoptive T-Cell Therapy.

Dörrie J, Babalija L, Hoyer S, Gerer KF, Schuler G, Heinzerling L, Schaft N.

Int J Mol Sci. 2018 Jan 18;19(1). pii: E289. doi: 10.3390/ijms19010289.

34.

Concealed complete response in melanoma patients under therapy with immune checkpoint inhibitors: two case reports.

Schliep S, Agaimy A, Cavallaro A, Kiesewetter F, Schuler G, Heinzerling L.

J Immunother Cancer. 2018 Jan 15;6(1):2. doi: 10.1186/s40425-017-0309-3.

35.

Das Interesse an Solarien und Sonnenschutz im deutschsprachigen Raum.

Kirchberger MC, Kirchberger LF, Eigentler TK, Reinhard R, Berking C, Schuler G, Heinzerling L, Heppt MV.

J Dtsch Dermatol Ges. 2017 Dec;15(12):1192-1198. doi: 10.1111/ddg.13380_g. No abstract available.

PMID:
29228492
36.

Can checkpoint inhibitor therapy improve response to chemotherapy?

Kirchberger MC, Schilling B, Haferkamp S, Bosserhoff A, Schuler G, Heinzerling L.

J Cancer Res Clin Oncol. 2018 Jan;144(1):183-185. doi: 10.1007/s00432-017-2546-8. Epub 2017 Nov 24. No abstract available.

PMID:
29177557
37.

Interest in tanning beds and sunscreen in German-speaking countries.

Kirchberger MC, Kirchberger LF, Eigentler TK, Reinhard R, Berking C, Schuler G, Heinzerling L, Heppt MV.

J Dtsch Dermatol Ges. 2017 Dec;15(12):1192-1198. doi: 10.1111/ddg.13380. Epub 2017 Nov 17.

PMID:
29148618
38.

Life-threatening Autoimmune Cardiomyopathy Reproducibly Induced in a Patient by Checkpoint Inhibitor Therapy.

Tajmir-Riahi A, Bergmann T, Schmid M, Agaimy A, Schuler G, Heinzerling L.

J Immunother. 2018 Jan;41(1):35-38. doi: 10.1097/CJI.0000000000000190.

PMID:
29077601
39.

Clinical characteristics and outcome of 60 pediatric patients with malignant melanoma registered with the German Pediatric Rare Tumor Registry (STEP).

Offenmueller S, Leiter U, Bernbeck B, Garbe C, Eigentler T, Borkhardt A, Classen CF, Corbacioglu S, Dirksen U, Ebetsberger-Dachs G, Heinzerling L, Jorch N, Kuhlen M, Lawlor J, Niggli F, Streiter M, Schneider DT, Brecht I.

Klin Padiatr. 2017 Nov;229(6):322-328. doi: 10.1055/s-0043-118662. Epub 2017 Oct 10.

PMID:
29017184
40.

Survival of metastatic melanoma patients after dendritic cell vaccination correlates with expression of leukocyte phosphatidylethanolamine-binding protein 1/Raf kinase inhibitory protein.

Buschow SI, Ramazzotti M, Reinieren-Beeren IMJ, Heinzerling LM, Westdorp H, Stefanini I, Beltrame L, Hato SV, Ellebaek E, Gross S, Nguyen VA, Weinlich G, Ragoussis J, Baban D, Schuler-Thurner B, Svane IM, Romani N, Austyn JM, De Vries IJM, Schuler G, Cavalieri D, Figdor CG.

Oncotarget. 2017 Jun 27;8(40):67439-67456. doi: 10.18632/oncotarget.18698. eCollection 2017 Sep 15.

41.

Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.

Heppt MV, Heinzerling L, Kähler KC, Forschner A, Kirchberger MC, Loquai C, Meissner M, Meier F, Terheyden P, Schell B, Herbst R, Göppner D, Kiecker F, Rafei-Shamsabadi D, Haferkamp S, Huber MA, Utikal J, Ziemer M, Bumeder I, Pfeiffer C, Schäd SG, Schmid-Tannwald C, Tietze JK, Eigentler TK, Berking C.

Eur J Cancer. 2017 Sep;82:56-65. doi: 10.1016/j.ejca.2017.05.038. Epub 2017 Jun 22.

PMID:
28648699
42.

Predictive value of PD-L1 based on mRNA level in the treatment of stage IV melanoma with ipilimumab.

Brüggemann C, Kirchberger MC, Goldinger SM, Weide B, Konrad A, Erdmann M, Schadendorf D, Croner RS, Krähenbühl L, Kähler KC, Hafner C, Leisgang W, Kiesewetter F, Dummer R, Schuler G, Stürzl M, Heinzerling L.

J Cancer Res Clin Oncol. 2017 Oct;143(10):1977-1984. doi: 10.1007/s00432-017-2450-2. Epub 2017 Jun 14.

PMID:
28616701
43.

Prognostic factors and treatment outcomes in 444 patients with mucosal melanoma.

Heppt MV, Roesch A, Weide B, Gutzmer R, Meier F, Loquai C, Kähler KC, Gesierich A, Meissner M, von Bubnoff D, Göppner D, Schlaak M, Pföhler C, Utikal J, Heinzerling L, Cosgarea I, Engel J, Eckel R, Martens A, Mirlach L, Satzger I, Schubert-Fritschle G, Tietze JK, Berking C.

Eur J Cancer. 2017 Aug;81:36-44. doi: 10.1016/j.ejca.2017.05.014. Epub 2017 Jun 7.

PMID:
28600969
44.

Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions.

Hassel JC, Heinzerling L, Aberle J, Bähr O, Eigentler TK, Grimm MO, Grünwald V, Leipe J, Reinmuth N, Tietze JK, Trojan J, Zimmer L, Gutzmer R.

Cancer Treat Rev. 2017 Jun;57:36-49. doi: 10.1016/j.ctrv.2017.05.003. Epub 2017 May 18. Review.

PMID:
28550712
45.

Twelve-year survival and immune correlates in dendritic cell-vaccinated melanoma patients.

Gross S, Erdmann M, Haendle I, Voland S, Berger T, Schultz E, Strasser E, Dankerl P, Janka R, Schliep S, Heinzerling L, Sotlar K, Coulie P, Schuler G, Schuler-Thurner B.

JCI Insight. 2017 Apr 20;2(8). pii: 91438. doi: 10.1172/jci.insight.91438. eCollection 2017 Apr 20.

46.

Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma.

Zimmer L, Apuri S, Eroglu Z, Kottschade LA, Forschner A, Gutzmer R, Schlaak M, Heinzerling L, Krackhardt AM, Loquai C, Markovic SN, Joseph RW, Markey K, Utikal JS, Weishaupt C, Goldinger SM, Sondak VK, Zager JS, Schadendorf D, Khushalani NI.

Eur J Cancer. 2017 Apr;75:47-55. doi: 10.1016/j.ejca.2017.01.009. Epub 2017 Feb 17.

PMID:
28214657
47.

Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity.

Gutzmer R, Koop A, Meier F, Hassel JC, Terheyden P, Zimmer L, Heinzerling L, Ugurel S, Pföhler C, Gesierich A, Livingstone E, Satzger I, Kähler KC; German Dermatooncology Group (DeCOG).

Eur J Cancer. 2017 Apr;75:24-32. doi: 10.1016/j.ejca.2016.12.038. Epub 2017 Feb 16.

PMID:
28214654
48.

Eosinophilic count as a biomarker for prognosis of melanoma patients and its importance in the response to immunotherapy.

Moreira A, Leisgang W, Schuler G, Heinzerling L.

Immunotherapy. 2017 Jan;9(2):115-121. doi: 10.2217/imt-2016-0138.

PMID:
28128709
49.

A review of serious adverse effects under treatment with checkpoint inhibitors.

Heinzerling L, Goldinger SM.

Curr Opin Oncol. 2017 Mar;29(2):136-144. doi: 10.1097/CCO.0000000000000358. Review.

PMID:
28059853
50.

The tanning habits and interest in sunscreen of Google users: what happened in 12 years?

Kirchberger MC, Heppt MV, Eigentler TK, Kirchberger MA, Schuler G, Heinzerling L.

Photodermatol Photoimmunol Photomed. 2017 Mar;33(2):68-74. doi: 10.1111/phpp.12289. Epub 2017 Jan 19.

PMID:
28039945

Supplemental Content

Loading ...
Support Center